We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » DDMAC Warnings Focus on Inadequate Risk Information
DDMAC Warnings Focus on Inadequate Risk Information
September 23, 2005
Drugmakers should craft their pharmaceutical promotions in a way that gives equal weight to a product’s risks and claims, suggests the head of the FDA’s advertising oversight division, which has ratcheted up its scrutiny of the product promotions in recent months.